Atlas of Rheumatoid Arthritis

1. Classification of rheumatoid arthritis
2. Pre-rheumatoid arthritis
- What is pre-rheumatoid arthritis?
- Risk factors for rheumatoid arthritis
- Systemic autoimmunity associated with rheumatoid arthritis
- Symptoms without clinical arthritis
- Unclassified arthritis
3. Early rheumatoid arthritis
- Introduction
- Pathology in early rheumatoid arthritis
- Diagnosis of early rheumatoid arthritis
- Classification of rheumatoid arthritis
- Management of early rheumatoid arthritis
- Recommendations for the management of early rheumatoid arthritis
4. Established rheumatoid arthritis
- Introduction
- Stages of established rheumatoid arthritis
- Common clinical presentations
- Introduction
- Stages of established rheumatoid arthritis
- Common clinical presentations
5. Remission and rheumatoid arthritis
- Introduction
- Defining remission
- Imaging remission
- Immune-mediated remission
- Drug-free remission
- Optimal dose reduction regimes for patients in remission
Part TWO Imaging of Rheumatoid Arthritis
6. Magnetic resonance imaging in rheumatoid arthritis
- Introduction
- Technical aspects
- Visualizing rheumatoid arthritis
- Diagnosing rheumatoid arthritis
- Monitoring disease activity and structural damage
7. Ultrasound imaging in rheumatoid arthritis
- Introduction
- Ultrasound and rheumatoid arthritis
- Cartilage damage
- Management of rheumatoid arthritis with ultrasound: diagnosis, therapeutic follow-up, remission, and flare
- Conclusion
8. Dual energy X-ray absorptiometry in rheumatoid arthritis
- Introduction
- Bone remodeling in rheumatoid arthritis
- Bone damage imaging in rheumatoid arthritis
- Treatment of bone loss in rheumatoid arthritis
Part three Treatment of rheumatoid arthritis
9. Methotrexate
- Introduction
- Historical perspective
- Mechanism of action and pharmacokinetics
- Dosing
- Benefits
- Monitoring
10. Immunotherapy
- Introduction
- Nonbiologic disease-modifying antirheumatic drugs
-

Professor Paul Emery is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the LeedsMusculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, UnitedKingdom. Professor Emery was the President of the European League Against Rheumatism(EULAR) from 2009-2011 and has served on the editorial boards major rheumatology journalsincluding Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinicaland Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President ofInternational Extremity MRI Society (ISEMIR) and is a National Institute for Health Research(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award forClinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULARPrize for outstanding contribution to rheumatology research; and the Carol Nachman Prizefor outstanding rheumatology research. Professor Emery's research interests center around theimmunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connectivetissue diseases. He has a special interest in the factors leading to persistent inflammationand has published over 950 peer-reviewed articles in this area.is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the LeedsMusculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, UnitedKingdom. Professor Emery was the President of the European League Against Rheumatism(EULAR) from 2009-2011 and has served on the editorial boards major rheumatology journalsincluding Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinicaland Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President ofInternational Extremity MRI Society (ISEMIR) and is a National